« Previous
Next »
Titles
- Assessing user fees under the Prescription Drug User Fee Amendments of 20171
- Drug industry: profits, research and development spending, and merger and acquisition deals : report to Congressional requesters1
- Getting to the root of high prescription drug prices: drivers and potential solutions1
- High-expenditure Medicare drugs often qualified for Orphan Drug Act incentives designed to encourage the development of treatments for rare diseases1
- Prescription Drug User Fee Act waivers, reductions, and refunds for drug and biological products1
- Prices for and spending on specialty drugs in Medicare Part D and Medicaid1
- Prices for and spending on specialty drugs in Medicare Part D and Medicaid: an in-depth analysis1